GlaxoSmithKline

GSK offers apprenticeships, internships, and graduate programs in Belgium, India, Poland, UK, and US. Use the job search for local early career openings.

GSK’s phase 1/2 trial of HSV vaccine candidate, GSK3943104, failed to meet primary efficacy endpoint, leading to discontinuation of further development. The trial will continue for safety monitoring.

CDE of China’s NMPA grants BTD for belantamab mafodotin-blmf plus Vd in relapsed/refractory multiple myeloma, based on DREAMM-7 trial data showing 36.6-month median PFS vs 13.4 months with DVd.

FDA approves Sanofi and AstraZeneca's new filling line for Beyfortus, enabling expanded manufacturing capacity and supply in the U.S. for the 2024/2025 RSV season. Beyfortus, a long-acting antibody, was FDA-approved in July 2023 for infants and children up to 24 months old at severe risk of RSV infection. CDC analysis in March 2024 showed Beyfortus 90% effective at preventing RSV hospitalization.

Moderna's mResvia RSV vaccine uptake slower than expected, facing challenges from GSK and Pfizer. Moderna executives acknowledge initial optimism and difficulties in contracting and CDC approval.

PDF document structure and metadata, including cross-reference table and stream objects.

Solid tumors market projected to reach $375.4B by 2034 with 7.45% CAGR. Aethlon Medical activates Hemopurifier trial at Royal Adelaide Hospital for solid tumor patients resistant to anti-PD-1 therapies. Immuneering reports positive initial data for IMM-1-104 in pancreatic cancer. FDA approves new immunotherapy combinations for endometrial cancer from AstraZeneca, Merck, and GlaxoSmithKline. Roche's trastuzumab deruxtecan receives accelerated approval for HER2-positive solid tumors.

Japan's health ministry accepts GSK's Blenrep NDA for blood cancer treatment, following EU and UK approvals. Blenrep granted orphan drug status in Japan, supported by DREAMM-7 and DREAMM-8 trials. GSK aims to expedite global regulatory pathways for Blenrep.

Japan's MHLW accepts GSK's NDA for Blenrep plus BorDex or PomDex for relapsed/refractory multiple myeloma, based on DREAMM-7 and DREAMM-8 trials. Blenrep shows potential to redefine treatment landscape.